Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.524 EUR | +0.45% | -15.34% | -60.94% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.94% | 474M | - | ||
+46.94% | 765B | C+ | ||
-6.69% | 354B | C+ | ||
+19.01% | 331B | B- | ||
+8.51% | 299B | C+ | ||
+18.74% | 248B | B+ | ||
-2.13% | 219B | A+ | ||
+10.90% | 216B | B- | ||
+4.71% | 164B | C+ | ||
-2.64% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EYPT Stock
- PV3B Stock
- Ratings EyePoint Pharmaceuticals, Inc.